{
  "image_filename": "figure_p2_det_1_000.png",
  "image_path": "CDC_Influenza_vaccines/extracted/figures/figure_p2_det_1_000.png",
  "image_type": "Figure",
  "page_number": 2,
  "block_id": "det_1_000",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A table listing influenza vaccine products by trade name and manufacturer (Fluad Quadrivalent, Flublok Quadrivalent, FluMist Quadrivalent), specifying presentation (volume, prefilled syringe or nasal spray), age indication, antigen content (\u00b5g HA or virus count), route of administration, and mercury content. does not support the claim because the table only provides product names, formulations, dosages, and administration routes and contains no data on immune response breadth or cross-protection in mismatch seasons.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table listing influenza vaccine products by trade name and manufacturer (Fluad Quadrivalent, Flublok Quadrivalent, FluMist Quadrivalent), specifying presentation (volume, prefilled syringe or nasal spray), age indication, antigen content (\u00b5g HA or virus count), route of administration, and mercury content.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table only provides product names, formulations, dosages, and administration routes and contains no data on immune response breadth or cross-protection in mismatch seasons.",
    "confidence_notes": null
  }
}